



Evaluation of an intensive voice treatment to reduce anterior drooling in children with cerebral palsy: Protocol for a concurrent multiple-baseline, single case experimental design study

Michelle McInerney^{a,*}, Christine Imms^d, Paul N Carding^c, Dinah S Reddihough^b

^a Lecturer in Speech Pathology, School of Allied Health, Australian Catholic University, Level 3 TWH, 8-20 Napier Street, North Sydney, NSW, 2060, Australia

^b The Royal Children's Hospital Melbourne, Department of Paediatrics, The University of Melbourne, Neurodisability and Rehabilitation, Murdoch Children's Research Institute, Melbourne, Australia

^c Professor of Speech Pathology, Director, Oxford Institute of Nursing, Midwifery and Allied Health Research (INMAHR), Oxford Brookes University, Oxford, UK

^d Apex Australia Chair of Neurodevelopment and Disability, Fellow, Occupational Therapy Australia Research Academy, Department of Paediatrics, The University of Melbourne, Australia

ARTICLE INFO

Keywords:

Drooling

Child

Cerebral palsy

Behavioral intervention

ABSTRACT

Anterior drooling is common in children with cerebral palsy (CP) and poses significant risks to the child's health. Causes of drooling include oro-motor dysfunction, inefficient swallowing and reduced sensation in the orofacial musculature. Behavioural interventions are frequently recommended to reduce drooling; however, this is in the absence of high-quality research evidence. This paper describes a protocol for evaluating the effectiveness of the Lee Silverman Voice Treatment LOUD (LSVT LOUD®) in reducing drooling; and optimising speech and swallowing in a group of children with CP. A structured and systematic visual analysis supplemented with statistical analyses will be used to analyse the data. The risk of bias in n-of-1 trials (RoBiNT) Scale [1] guided the design and implementation of the study.

1. Introduction

Many children with cerebral palsy (CP) experience difficulties controlling saliva [2,3]. Potential reasons for this clinical feature of CP include: a reduction in swallowing ability [4]; oral motor dysfunction [5]; and reduced sensation in oro-facial musculature [6] resulting in the anterior loss of saliva from the mouth [7]. Drooling can be a disabling condition for children with CP adversely affecting physical and emotional health [8], social interactions and self-esteem [9,10]. Health impacts include skin maceration and breakdown, skin infection [11], and social rejection from peers [9]. Drooling has also been shown to increase the care needs of the child, putting families under increased stress [12]. Thus, drooling has the potential to reduce the quality of life of both children with CP, and their families.

A treatment approach that holds promise in improving swallowing and reducing drooling in children with CP is the Lee Silverman Voice Treatment LOUD (LSVT LOUD®). This intensive voice treatment has already been developed, piloted, reported and implemented, and has demonstrated level I evidence in facilitating positive long-term effects

on loudness of speech in adult patients with Parkinson's disease [13–16]. LSVT LOUD® is founded on principles of behavioural theories of learning, motor learning and neuroplasticity [17,18]. Sixteen 60-min treatment sessions per month are implemented, that is, four sessions a week for four consecutive weeks; and each treatment session involves both isolated and functional voice-exercises [15]. Ten to 15 min of daily homework practice is an important part of the treatment [16,17]. Clinical outcome research has highlighted similar speech outcomes in children with CP [19–22]. Importantly, cross-generalised effects of LSVT LOUD® to non-targeted skills such as oral motor movements and swallowing have also been reported in adults with Parkinson's disease [23–25]. As reduced swallowing function is a key contributing factor to anterior drooling in children with CP, behavioural interventions such as LSVT LOUD® that optimise swallowing, may also facilitate better management of saliva within the oral cavity, and thereby potentially reduce the anterior spillage of salivary contents, or drooling, in children with CP.

This paper presents a protocol to evaluate the effects of LSVT LOUD® on the target behaviours; drooling severity and impact; swallowing and feeding competency; and speech intelligibility at single word, sentence

* Corresponding author.

E-mail address: Michelle.McInerney@acu.edu.au (M. McInerney).

Abbreviations used in text	
CP	Cerebral Palsy
LSVT LOUD®	Lee Silverman Voice Treatment LOUD (LSVT LOUD®)
ICF CY	International Classification of Functioning, Disability and Health- Child & Youth Version
SCED	Single case experimental design
RoBiNT	Risk of bias in n-of-1 trials (RoBiNT)
AusTOMS	Australian Therapy Outcome Measures for Speech Pathology
DQ5 ^A	Drooling Quotient (Five-minute: Activity)
NSW	New South Wales
ACT	Australian Capital Territory
FDA-2	Frenchay-Dysarthria Assessment-2nd edition

and conversational level. It is anticipated that the current project will contribute to evidence for managing and treating drooling, and build on existing evidence in the treatment of motor speech impairments in children with CP. The International Classification of Functioning, Disability and Health- Child & Youth Version (ICF-CY) (World Health Organization [26] provided the conceptual framework for the study.

2. Methods

2.1. Study design

A single case experimental design (SCED) involves the repeated measurement of an individual’s behaviour in the presence and absence of the intervention, thereby enabling the individual to serve as their own control [27]. A concurrent multiple baseline SCED will be used to investigate the effects of LSVT LOUD® on the primary outcome of drooling, and the secondary outcomes of swallowing and speech. The application of randomization will be made to phase onset with the starting point of intervention differing for each participant (see Fig. 1 below). The baseline phase will be followed immediately by a 16-session treatment period over four weeks. The follow up period will take place 12-weeks after the last treatment session has taken place. Concealed randomisation will be used to allocate each participant to one of three treatment baseline conditions: a baseline length of 10 days, 14 days or 18 days, which means the starting point of intervention will be staggered, and different for each participant in each set of three. All participants will begin the baseline phase on the same day. A concurrent design enhances internal validity by controlling for maturation effects and minimizing environmental influences [1,28].




Fig. 1. Randomization of participants to treatment (Tx) conditions. Participants will be randomized to one of two samples of three participants. Within each sample participants will be randomly allocated to one of three baseline conditions: a 10-day, 14-day, or 18-day baseline.

2.2. Participants and recruitment

Ethical approval for this study has been received from the Australian Catholic University (ACU) (ref: 2018-142H) and the Cerebral Palsy Alliance (CPA) (ref: 2018-08-03). Six children between the ages of 7 and 18 years with a diagnosis of CP who have problematic drooling and who live in Sydney, Australia will be sought. The six participants will be recruited in two samples of three participants (n = 6). SCED studies require three opportunities to demonstrate an experimental effect to establish adequate experimental control [1]. This study involves multiple baselines across participants, which necessitates having at least three participants. By increasing the number of participants to six, there is increased opportunity to observe whether the dependent variable changes after the introduction of treatment, hence demonstrating a greater potential to capture evidence of a treatment effect. Additional participants provide increased strength of the evidence and six participants was feasible for this study.

Inclusion criteria: (i) confirmed diagnosis of CP (all classifications and severities considered); (ii) Intelligence Quotient (IQ) falling within the average to moderate range of disability; (iii) evidence of frequent anterior drooling as determined by parent or child and affecting the child’s physical or social health; (iv) parental report of stable drooling severity over the past 3 months; (v) aged 7–18 years; (vi) Level I or II communicators on the Communication Function Classification System (CFCS) [29]; (vii) verbal communicators who are able to produce an ‘ah’ vocalisation; (viii) language: have the ability to produce at least 3–4 worded utterances; (ix) speech: overall speech intelligibility must be greater than 30% on the Australian Therapy Outcome Measures for Speech Pathology (AusTOMS) [30] speech impairment measure (2-min conversational sample); (x) demonstrated high compliance with previous speech pathology interventions (as pre-determined by parent and/or speech pathologist); (xi) ability to maintain independent head control; and (xii) hearing within normal limits/no dual diagnosis of hearing impairment.

Exclusion criteria: (i) intellectual ability is greater than mild impairment; (ii) presence of additional vocal pathology e.g., vocal nodules; (iii) history of hoarse voice; (iv) inconsistent drooling (periods when drooling is not present); (v) currently on medications that cause drooling e.g., clonazepam; or (vi) currently receiving other treatment for drooling e.g., block of oral sensory motor therapy.

Advertisements in the monthly newsletter, together with the participant information letter and consent forms, will be sent to the Cerebral Palsy Alliance (CPA) and to the New South Wales (NSW)/Australian Capital Territory (ACT) CP Register for distribution. Interested parties will be invited to contact the lead researcher. If needed, the advertisement will also be sent to schools for children with developmental disability in the Sydney metropolitan area following relevant approvals. Once interest is solicited, the lead researcher will email or mail the participant information letters and consent forms for participants and their parent(s)/caregiver(s) to the interested families. For those participants not able to provide written informed consent, verbal assent will be obtained from the participant and documented; and the parent/guardian will be asked to complete an informed consent form. Following brief telephone screening, completed by the lead researcher (MM), individuals will be informed that they are, or are not, eligible by the lead researcher over the phone. Recruitment will cease after the enrolment of the six participants.

2.3. Data collection

Each data collection and treatment session for each participant will be audio- and videorecorded. Quantitative data on drooling, swallowing and speech will be collected for each participant in three phases; (1) baseline (2) intervention and (3) follow up. Five repeated measures of drooling will be taken; and three repeated measures of each of the swallowing and speech variables will be taken in each phase. An assessor

(research assistant) who is independent of the interventionist will collect all data on primary and secondary outcomes (See Fig. 2 below). The interventionist will be a speech pathologist who is trained in both LSVT LOUD® and the online treatment version (LSVT e- LOUD®). A daily treatment protocol sheet from the LSVT LOUD® treatment manual will be used as a guide in each treatment session, whereby each ingredient is checked off against the protocol to capture data on what was implemented.

3. Dependent variables and outcome measures

Detailed baseline data related to drooling, speech and swallowing will be collected after enrolment and prior to commencement of the baseline data collection. After participants are enrolled in the study, a case history form will be sent to each parent to complete and they will be asked to return it to the lead researcher. The case history questionnaire was created by the lead researcher and included questions about the child’s relevant medical history and demographic details. The questionnaire content is also based on the following relevant measures: The Saliva Control Assessment form [31]; The Drooling Frequency and Severity Scale [32]; Communication Function Classification System [29]; and AusTOMs [30]. A follow up phone call will be conducted with each parent to verify responses on the case history form and facilitate accuracy in the recording of baseline data.

The primary dependent variables in this study are *anterior drooling*, or the anterior spillage of saliva beyond the lip margin; and *drooling impact*, or the influence of drooling on the individual’s life as perceived by a parent. Secondary dependent variables are related to speech intelligibility and swallowing. Single-word speech intelligibility is defined as the perceived clarity of speech at a single word level; sentence intelligibility, clarity of speech at sentence level, and conversational speech intelligibility referred to clarity of speech at a conversational level. Swallowing and feeding competency is defined as the task components of oral preparatory, oral and pharyngeal phases of swallowing.

Drooling Quotient Five-minute: Activity (DQ5^A) [33]: Measure of Drooling Severity (Body Functions & Structures (BFS) Level): The DQ5^A is an objective valid measure of drooling frequency and severity for children with CP and other developmental disabilities. It is an observational tool whereby a trained observer records the number of times the individual drools over a 5-min period whilst they are undertaking a preferred activity in a sitting position (e.g., building a block tower, reading out loud). The DQ5^A has been demonstrated to be a

sensitive and specific measure of drooling severity (0.61 and 0.75 respectively using Youden Index^{1*}). Drooling episodes are counted as present when saliva is visualised beyond the lip margin. A score of ‘1’ is given for episodes where drooling occurs and ‘0’ for no drooling. A drooling ‘quotient’ score is expressed as a percentage of observed drooling episodes (intervals with new saliva) and the total number of intervals (0 = no new saliva, 100 = 100% of the intervals new saliva) [33]. The Drooling Quotient has good test-retest reliability in children who have stable drooling with the intra-rater intraclass correlation coefficient (ICC) reported to be > 0.86 [33].

The Drooling Impact Scale (Dri Scale) [34]: The Dri Scale [34] is a subjective measure of the impact of drooling in children with neurological conditions. It is a parent-completed questionnaire consisting of 10 items, to rate the degree to which drooling has affected their life over the previous week on a 10-point scale (1 = not at all, 10 = constantly). Examples of questions include ‘How much skin irritation has your child had due to drooling?’. It takes 5 min to complete. The Dri Scale is valid, reliable and responsive to change in children with developmental disabilities who have undergone saliva control interventions. It has demonstrated good face, content and construct validity, with significant correlations between scores and carer’s global ratings of change (0.69, p < 0.001). It has good test-retest reliability in children who have stable drooling [34] with the ICC reported to be 0.95 [34].

Dysphagia Disorders Survey (DDS) [35] (BFS & Activity Level): The Dysphagia Disorders Survey (DDS) [35] is a standardized screening tool of swallowing and feeding disorders in children with developmental disability. The individual is observed having something to eat and drink, and the certified clinician completes a 15-item survey on their swallowing and feeding skills. The DDS takes 10–15 min to complete. For each item, the clinician rates 0 for ‘good function’ or ‘1’ for deficient function (definitions of what constitutes ‘good’ and ‘deficient’ are provided in the manual). This provides a numerical score and percentile rankings for swallowing and feeding abilities in children and adults with developmental disability. The DDS [35] has strong internal consistency, with a Cronbach alpha score of 0.89 for part 2, and demonstrates high-sensitivity, specificity, positive and negative predictive values [35]. The DDS meets the criteria for face, content, convergent and construct validity. Inter-rater reliability is good, with an average ICC of 0.97 [35].

Frenchay-Dysarthria Assessment-2nd edition (FDA-2) [36]: Perceptual assessment is central to the evaluation of speech outcomes [37]. Data on speech intelligibility of untrained spoken items (single word, sentence and conversational level) will be collected. The intelligibility subtest from the FDA-2 [3] was chosen to assess intelligibility at a single word, sentence-level and conversational level. This was chosen as a) no validated measure was available for both age range of participants and diagnosis b) stimulus items in subtest are phonetically balanced to provide a more reliable sample of speech intelligibility and c) previous research completed with children with CP has shown the subtest to be a feasible measure [38]. In assigning a perceptual rating, the clinician then judges the person’s intelligibility at each level using a 5-point Likert scale. This scale will also be used to judge the intelligibility of trained speaking items (phrase/sentence level intelligibility) before, during and after the intervention. The validity and reliability of the FDA has been established by several studies with diagnostic groups with differing neurological conditions, for example, with stroke [39]. The FDA-2 has good inter-rater reliability agreement with an average ICC of 91% (0.91) [36].




Fig. 2. Example of data collection plan for one participant.

¹ The Youden Index is the likelihood of a positive test result in persons with the condition versus those without the condition. It combines sensitivity and specificity into a single measure and has a value between 0 and 1 (a score of 1 being the perfect score).

4. Data analysis

In a SCED, data are evaluated by comparing an individual's performance during the baseline with performance during the experimental phase [40]. A systematic visual analysis is the traditional method of interpreting the effects of interventions using SCEDs [1,41], and is considered the gold standard for assessing quantitative procedures [42, 43]. Data collected on drooling (frequency and severity), swallowing (oral preparatory, oral and oropharyngeal stages of swallows) and speech (word, sentence, conversational intelligibility) measures will be entered into SPSS and graphic displays will be produced e.g., line graphs. Five visual inspection criteria will be completed to facilitate a systematic visual analysis and will include the evaluation of level, trend, variability and immediacy of effect (see Table 1 below). This systematic examination of graphed data enables the level of functional relationship between the manipulation of an independent variable and a change in the dependent variable to be assessed. It also facilitates judgment as to whether there is strong, moderate, or no, evidence for a treatment effect on drooling, swallowing and speech. One supplemental statistical method, the Tau method, a robust non-overlap index method that can control for undesirable positive baseline trend [44] will also be employed. In line with recommendations, data will be assessed for baseline trend, and if all non-significant, the Tau-U A vs. B will be used. An indication of behavioural change due to the intervention will not be made based on a change in mean scores alone but will be guided by the collective evidence of an intervention effect considering documented change in other visual inspection criteria outlined in Table 1, and the determination of an effect as determined by Tau calculations. Results on all measures will be tabulated and descriptive statistics including measures of central tendency will be presented for each of the four measures.

5. Discussion

Anterior drooling is common and significantly affects the health of children with CP. Behavioural intervention is a sound theoretical non-invasive approach for treating drooling but supported by low-level research evidence. High-quality experimental studies on the effectiveness of interventions to treat anterior drooling are urgently needed. This paper describes a study protocol for the evaluation of an intensive voice treatment, LSVT LOUD®, targeting drooling, speech, and swallowing in children with CP using a concurrent multiple baseline SCED. To our knowledge, there is no previous research evaluating the effects of LSVT LOUD® on anterior drooling in children with CP. Our hypothesis is that LSVT LOUD® will reduce anterior drooling in children with CP. The assessment of methodological quality using the (RoBiNT) Scale [1] directly informed the conceptual development and planning of this intervention study. It will facilitate addressing some of the methodological pitfalls of previous research to optimise the internal and external validity of the intervention study including providing relevant baseline characteristics, blinding outcome assessors and optimising sampling of data.

SCEDs are a useful alternative experimental design choice when evaluating intervention effectiveness [46,47]. SCEDs are advantageous when compared to group-level designs for numerous reasons. This experimental research design is very suitable when there is little known about an intervention's effects and can provide a more accurate assessment of the impact of an intervention for each individual [48,49]. SCEDs are useful when conducting research with low-incidence heterogeneous populations and can be delivered at relatively low-cost. Importantly, when implemented rigorously, SCEDs can also provide level 1 evidence regarding an intervention's effectiveness [50]. Collectively, these reasons highlight the SCED to be a worthwhile and valid method of testing the effectiveness of interventions. It is anticipated that this protocol will assist other researchers who are using a SCED method to evaluate the effects of interventions in early phases of clinical outcome research.

Table 1
Visual inspection criteria.

Criterion	Definition
Stability	Baseline data for each behaviour describe the current level of performance and predict future performance, and it is important that baseline data are relatively stable. Little variability and the absence of trend indicate a stable rate of performance. The stability envelope will be calculated for each outcome in each phase. For stability, 80% data must fall within 25% of median value for that phase [45].
Changes in means across phases	Mean rate of the behaviour shows a change from phase to phase in the expected direction.
Change in trend (slope)	Direction of slope changes from phase to phase, for example, no slope (horizontal line) in baseline and an accelerating/increasing slope during intervention phase indicates a change in behaviour with introduction of the intervention. Trend also refers to rate of change/progress.
Shift in level	A level refers to the change in behaviour (dependent variable value) from the last day of one phase, e.g. baseline, and the first day of the next phase, e.g. intervention. An abrupt shift facilitates interpretation of an effect from treatment.
Latency of change	Period of time between the onset or end of one phase and changes in performance (e.g., from baseline to intervention). The closer in time that behaviour change occurs after the conditions have been altered, the easier it is to attribute the change to the intervention.

Funding

This work was supported by a National Health and Medical Research Council (NHMRC) funded Centre of Research Excellence in Cerebral Palsy (CRE CP) PhD Scholarship to investigate saliva control interventions for children with CP. The funding sources had no role in determining the study design; data collection or analysis; in the writing of the protocol; and in the decision to submit the article for publication.

Declaration of competing interest

The authors declare that there is no conflict of interest.

References

- [1] R.L. Tate, The Risk-Of-Bias in N-Of-1 Trials (RoBiNT) Scale : an Expanded Manual for the Critical Appraisal of Single-Case Reports, John Walsh Centre for Rehabilitation Research, St Leonards NSW, 2015.
- [2] S.M. Reid, J. McCutcheon, D.S. Reddihough, H.M. Johnson, Prevalence and predictors of drooling in 7- to 14-year-old children with cerebral palsy: a population study, *Dev. Med. Child. Neurol.* 54 (11) (2012) 1032–1036.
- [3] D. Reddihough, H. Johnson, E. Ferguson, The role of a saliva control clinic in the management of drooling, *J. Paediatr. Child Health* 28 (5) (1992) 395–397.
- [4] J.E. Senner, J. Logemann, S. Zecker, D. Gaebler-Spira, Drooling, saliva production, and swallowing in cerebral palsy, *Dev. Med. Child Neurol.* 46 (12) (2004) 801–806.
- [5] C.E. Erasmus, K. Van Hulst, L.J.C. Rotteveel, P.H. Jongerius, F.J.A. Van Den Hoogen, N. Roeleveld, J.J. Rotteveel, Drooling in cerebral palsy: hypersalivation or dysfunctional oral motor control? *Dev. Med. Child Neurol.* 51 (6) (2009) 454–459.
- [6] R. Weiss-Lambrou, S. Tétrault, J. Dudley, The relationship between oral sensation and drooling in persons with cerebral palsy, *Am. J. Occup. Ther.* 43 (3) (1989) 155–161. Official Publication Of The American Occupational Therapy Association.
- [7] D.S. Reddihough, H.M. Johnson, Assessment and management of saliva control problems in children and adults with neurological impairment, *J. Dev. Phys. Disabil.* 11 (1) (1999) 17–24.
- [8] M.S. McInerney, D.S. Reddihough, P.N. Carding, R. Swanton, C.M. Walton, C. Imms, Behavioural interventions to treat drooling in children with neurodisability: a systematic review, *Dev. Med. Child Neurol.* 61 (1) (2019) 39–48.
- [9] J.J. Van der Burg, P.H. Jongerius, J. Van Limbeek, K. Van Hulst, J.J. Rotteveel, Social interaction and self-esteem of children with cerebral palsy after treatment for severe drooling, *Eur. J. Pediatr.* 165 (1) (2006) 37–41.
- [10] P.A. Blasco, J.H. Allaire, Drooling in the developmentally disabled: management practices and recommendations, *Dev. Med. Child Neurol.* 34 (1992) 849–862.
- [11] D. Manrique, J. Sato, Salivary gland surgery for control of chronic pulmonary aspiration in children with cerebral palsy, *Int. J. Pediatr. Otorhinolaryngol.* 73 (9) (2009) 1192–1194.
- [12] J.J. Van der Burg, P.H. Jongerius, J. Van Limbeek, K. Van Hulst, J.J. Rotteveel, Drooling in children with cerebral palsy: a qualitative method to evaluate parental

- perceptions of its impact on daily life, social interaction, and self-esteem, *Int. J. Rehabil. Res.* 29 (2) (2006) 179–182.
- [13] L. Ramig, C.M. Fox, O.032 Intensive voice treatment for Parkinson disease (LSVT LOUD): a neuroplasticity principled approach supported by technology, *Parkinson. Relat. Disord.* 15 (2009), S9–S9.
- [14] L. Ramig, E.S. Levy, C.M. Fox, A. Halpern, J. Spielman, G. Moya-Gale, A. Goudarzi, Impact of LSVT LOUD and LSVT ARTIC on speech intelligibility in Parkinson's disease, *Mov. Disord.* 30 (2015) S112–S113.
- [15] L. Ramig, S. Sapis, S. Countryman, A.A. Pawlas, C. O'Brien, M. Hoehn, L. L. Thompson, Intensive voice treatment (LSVT®) for patients with Parkinson's disease: a 2 year follow up, *J. Neurol. Neurosurg. Psychiatr.* 71 (4) (2001) 493.
- [16] E.S. Levy, Implementing two treatment approaches to childhood dysarthria, *Int. J. Speech-Lang. Pathol.* 16 (4) (2014) 344–354, translating knowledge to practice in childhood dysarthria. Guest editors: Angela Morgan, Megan Hodge, and Lindsay Pennington.
- [17] L. Ramig, S. Sapis, C.M. Fox, S. Countryman, Changes in vocal loudness following intensive voice treatment (LSVT®) in individuals with Parkinson's disease: a comparison with untreated patients and normal age-matched controls, *Mov. Disord.* 16 (1) (2001) 79–83.
- [18] J.R. Duffy, *Motor Speech Disorders : Substrates, Differential Diagnosis, and Management*, fourth ed., Elsevier, St. Louis, Missouri, 2020.
- [19] C.M. Fox, C.A. Boliek, Technology-enhanced maintenance practice following intensive voice therapy (LSVT LOUD) in children with cerebral palsy and dysarthria, *Mov. Disord.* 30 (2015), S205–S205.
- [20] E.S. Levy, L. Ramig, S.M. Camarata, The effects of two speech interventions on speech function in pediatric dysarthria. (Report), *J. Med. Speech - Lang. Pathol.* 20 (4) (2012) 82.
- [21] C.A. Boliek, C.M. Fox, Therapeutic effects of intensive voice treatment (LSVT LOUD®) for children with spastic cerebral palsy and dysarthria: A phase I treatment validation study, *Int. J. Speech-Lang. Pathol.* 19 (6) (2017) 601–615.
- [22] C.M. Fox, C.A. Boliek, Intensive voice treatment (LSVT LOUD) for children with spastic cerebral palsy and dysarthria, *J. Speech, Lang. Hear. Res.* 55 (3) (2012) 930–945.
- [23] A. El Sharkawi, L. Ramig, J.A. Logemann, B.R. Pauloski, A.W. Rademaker, C. H. Smith, A. Pawlas, S. Baum, C. Werner, Swallowing and voice effects of lee silverman voice treatment (LSVT®): a pilot study, *J. Neurol. Neurosurg. Psychiatr.* 72 (1) (2002) 31.
- [24] S. Sapis, L. Ramig, C.M. Fox, The Lee Silverman Voice Treatment® for voice, speech and other orofacial disorders in patients with Parkinson's disease, *Future Neurol.* 1 (5) (2006) 563–570.
- [25] D. McCabe, Facial Expressivity in Parkinson's Disease: Using the Facial Action Coding System to Evaluate Duchenne Smiling Behavior and the Impact of Voice Treatment upon Global Expressivity Measures at 6-month Follow-Up, ProQuest Dissertations Publishing, 2013.
- [26] World Health Organization, *International Classification of Functioning Disability and Health: Child and Youth Version, ICF-CY*, 2007.
- [27] A. Krasny-Pacini, J. Evans, Single-case experimental designs to assess intervention effectiveness in rehabilitation: a practical guide, *Ann. Phys. Rehabil. Med.* 61 (3) (2017) 164–179, <https://doi.org/10.1016/j.rehab.2017.12.002>.
- [28] K.M. Clanchy, S.M. Tweedy, R.L. Tate, M. Sterling, M.A. Day, J. Nikles, C. Ritchie, Evaluation of a novel intervention to improve physical activity for adults with whiplash associated disorders: protocol for a multiple-baseline, single case experimental study, *Contemp. Clin. Trials Commun.* 16 (2019), 100455–100455.
- [29] M. Hidecker, N. Paneth, P. Rosenbaum, R. Kent, J. Lillie, J. Eulenberg, K. Chester, B. Johnson, L. Michalsen, M.L. Evatt, K. Taylor, Developing and validating the communication function classification System for individuals with cerebral palsy, *Dev. Med. Child Neurol.* 53 (8) (2011) 704–710.
- [30] A. Perry, J. Skeat, *AusTOMs for Speech Pathology*, La Trobe University 2004.
- [31] H. Johnson, A. Scott, *A Practical Approach to Saliva Control, Communication Skill Builders*, Tuscon, AZ, 1993.
- [32] N. Thomas-Stonell, J. Greenberg, Three treatment approaches and clinical factors in the reduction of drooling, *Dysphagia* 3 (2) (1988) 73–78.
- [33] K. Van Hulst, R. Lindeboom, J.J. Van der Burg, P.H. Jongerius, Accurate assessment of drooling severity with the 5-minute drooling quotient in children with developmental disabilities, *Dev. Med. Child Neurol.* 54 (12) (2012) 1121–1126.
- [34] S.M. Reid, H.M. Johnson, D.S. Reddihough, The Drooling Impact Scale: a measure of the impact of drooling in children with developmental disabilities, *Dev. Med. Child. Neurol.* 52 (2) (2010) e23–e28.
- [35] J.J. Sheppard, R. Hochman, C. Baer, The Dysphagia Disorder Survey: validation of an assessment for swallowing and feeding function in developmental disability, *Res. Dev. Disabil.* 35 (5) (2014) 929–939.
- [36] P.M. Enderby, in: Pro (Ed.), *Frenchay Dysarthria Assessment [Test]*, second ed., Austin, Texas, 2008.
- [37] D. Sell, Issues in perceptual speech analysis in cleft palate and related disorders: a review, *Int. J. Lang. Commun. Disord.* 40 (2) (2005) 103–121.
- [38] R. Mary Watson, L. Pennington, Assessment and management of the communication difficulties of children with cerebral palsy: a UK survey of SLT practice, *Int. J. Lang. Commun. Disord.* 50 (2) (2015) 241–259.
- [39] L.A. Mahler, L. Ramig, Intensive treatment of dysarthria secondary to stroke, *Clin. Linguist. Phonet.* 26 (8) (2012) 681–694.
- [40] A.E. Kazdin, Single-case experimental designs. Evaluating interventions in research and clinical practice, *Behav. Res. Ther.* 117 (2019) 3–17.
- [41] A.M. Lobo, A.M. Moeyaert, A.A. Baraldi Cunha, A.I. Babik, Single-case design, analysis, and quality assessment for intervention research, *J. Neurol. Phys. Ther.* 41 (3) (2017) 187–197.
- [42] B. Michiels, P. Onghena, Nonparametric meta-analysis for single-case research: confidence intervals for combined effect sizes, *Behav. Res.* 51 (3) (2019) 1145–1160.
- [43] R. Manolov, P. Onghena, Analyzing data from single-case alternating treatments designs, *Psychol. Methods* 23 (3) (2018) 480–504.
- [44] K.R. Tarlow, An improved rank correlation effect size statistic for single-case designs: baseline corrected Tau, *Behav. Modif.* 41 (4) (2017) 427–467.
- [45] J.D. Lane, D.L. Gast, Visual analysis in single case experimental design studies: brief review and guidelines, *Neuropsychol. Rehabil.* 24 (3–4) (2014) 445–463.
- [46] J. Smith, M.I. Appelbaum, S.E. Maxwell, Single-case experimental designs: a systematic review of published research and current standards, *Psychol. Methods* 17 (4) (2012) 510–550.
- [47] T. Kratochwill, J.R. Levin, *Single-case Intervention Research: Methodological and Statistical Advances*, American Psychological Association, 2014.
- [48] W.F. Velicer, P. Molenaar, Time series analysis. Research methods in psychology, in: J. Schinka, W.F. Velicer, I.B. Weiner (Eds.), *Handbook of Psychology*, 2013.
- [49] M. Harrington, W.F. Velicer, Comparing visual and statistical analysis in single-case studies using published studies, *Multivariate Behav. Res.* 50 (2) (2015) 162–183.
- [50] J. Howick, I. Chalmers, P. Glasziou, T. Greenhalgh, C. Heneghan, A. Liberati, I. Moschetti, B. Phillips, H. Thornton, O. Goddard, M. Hodgkinson, *The Oxford 2011 levels of evidence*. <http://www.cebm.net/index.aspx?o=5653>, 2011, 5th April 2018.